Cutia Therapeutics (HKSE:02487) Interest Coverage: 0 (At Loss) (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02487 Cutia Therapeutics HKSE:02487
40 GF Score
Price HK$2.61
GF Value HK$16.27
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Cutia Therapeutics Interest Coverage?

Cutia Therapeutics HKSE:02487 +6.10% 40 Interest Coverage is 0 (At Loss) as of Dec. 2025. GuruFocus rates HKSE:02487 with a GF Score™ of 40/100 and a GF Value™ of HK$16.27 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 376 Biotechnology companies, Cutia Therapeutics ranks worse than 265957.18% on this metric.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Cutia Therapeutics's Operating Income for the six months ended in Dec. 2025 was HK$-105.1 Mil. Cutia Therapeutics's Interest Expense for the six months ended in Dec. 2025 was HK$-5.3 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Cutia Therapeutics's Interest Coverage or its related term are showing as below:


HKSE:02487's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 104.025
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Cutia Therapeutics  (HKSE:02487) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Cutia Therapeutics Interest Coverage Related Terms


Cutia Therapeutics Interest Coverage Historical Data

* Premium members only.

The historical data trend for Cutia Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Cutia Therapeutics Interest Coverage Chart

Cutia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Interest Coverage
0.00 0.00 0.00 0.00 0.00

Cutia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Coverage Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

HKSE:02487 vs VRTX, REGN, ALNY: Interest Coverage Comparison

For the Biotechnology subindustry, Cutia Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cutia Therapeutics Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Cutia Therapeutics's Interest Coverage falls into.


HKSE:02487
40GF Score
Cutia Therapeutics HKSE:02487
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cutia Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cutia Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, Cutia Therapeutics's Interest Expense was HK$-10.7 Mil. Its Operating Income was HK$-321.2 Mil. And its Long-Term Debt & Capital Lease Obligation was HK$149.4 Mil.

Cutia Therapeutics did not have earnings to cover the interest expense.

Cutia Therapeutics's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Here, for the six months ended in Dec. 2025, Cutia Therapeutics's Interest Expense was HK$-5.3 Mil. Its Operating Income was HK$-105.1 Mil. And its Long-Term Debt & Capital Lease Obligation was HK$149.4 Mil.

Cutia Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Frequently Asked Questions Learn more about Interest Coverage →
What does a Interest Coverage of 0 (At Loss) mean?
Cutia Therapeutics (HKSE:02487) has a Interest Coverage of 0 (At Loss) as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Cutia Therapeutics and its competitors. According to the industry distribution chart, Cutia Therapeutics ranks #999999 out of 376 companies in the Biotechnology industry.
Is Cutia Therapeutics' Interest Coverage too high?
Cutia Therapeutics' current Interest Coverage is 0 (At Loss). Based on the distribution chart, Cutia Therapeutics ranks #999999 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cutia Therapeutics has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cutia Therapeutics' Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cutia Therapeutics ranks #999999 out of 376 companies for Interest Coverage. This places Cutia Therapeutics in the lower half of its industry. The industry median Interest Coverage is 104.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 104.03, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Cutia Therapeutics and its competitors. For the Biotechnology industry, the median Interest Coverage is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cutia Therapeutics's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cutia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Cutia Therapeutics (HKSE:02487) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.27, compared to a current price of HK$2.61 — trading 84% below its estimated fair value. The current Interest Coverage is 0 (At Loss). Cutia Therapeutics' overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Cutia Therapeutics (HKSE:02487), the current Interest Coverage is 0 (At Loss) as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cutia Therapeutics (HKSE:02487) Overvalued in 2026?

Based on GuruFocus' analysis, Cutia Therapeutics stock appears to be undervalued. The current stock price of HK$2.61 is trading 84% below its estimated GF Value™ of HK$16.27. GuruFocus considers Cutia Therapeutics to be Possible Value Trap.

Key valuation signals for HKSE:02487:

  • Interest Coverage: 0 (At Loss)
  • GF Value™: HK$16.27 vs. price of HK$2.61 (84% below fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the HKSE:02487 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cutia Therapeutics Business Description

Address 436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070
Cutia Therapeutics is an investment holding company. The Company and its subsidiaries are principally engaged in developing inventive and comprehensive solutions that are tailored to meet the diverse and evolving needs of patients and consumers in the broader dermatology treatment and care market. It has a proprietary CATAME technology platform, which includes: Colloidal-Emulsification-Active Encapsulation (CEAE) platform, Aerosol (ARS) platform, Transdermal Delivery (TDD) platform, Actives & Formulation Evaluation (AFE) platform, Micro/Nano-Particulates & Self-Assembly (MiSA) platform, and Ex vivo & Efficacy Evaluation (EVEE) platform. It enables the development of a wide range of product dosage forms and the relevant formulation technology.
40GF Score

Get the complete analysis for HKSE:02487

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.61
Price
HK$16.27
GF Value